• Pfizer-BioNTech: safe vaccine for children between 5 and 11 years

  • Vaccini, Ema approves two production sites for BioNtech-Pfizer

  • Who are the two German scientists of Turkish origin behind the Pfizer / BioNTech vaccine

Share

by Tiziana Di Giovannandrea

15 October 2021 Pfizer and BioNTech companies have announced that they have presented to the European Medicines Agency-Ema the results of clinical tests conducted, with the vaccine they produce, on children between 5 and 11 years of age in order to obtain a variation of the conditional marketing authorization in the European Union and make Comirnaty * available in this age group.



In the study, the amount of vaccine administered to children is considerably lower than that given to adults, in fact the dosage is equal to one third of that inoculated to the older ones. The same companies have made it known. Currently, no vaccines have been authorized in Europe for this age group.



If approved by the EMA, it would be the first opportunity for children in the European Union to be vaccinated against Coronavirus.



Among the data presented to obtain the green light for the use of the vaccine, there are also the results of a final phase study on over 2,200 children aged between 6 months and 11 years. The companies said the results showed "a strong immune response" in the children and that the vaccine would be safe.



Rezza: "Good data on children's vaccines, it will help control the epidemic but it is yet to understand how necessary it is to do so" 


Gianni Rezza, Director General of Prevention of the Ministry of Health highlighted how: "At least one of the 'anti-Covid' mRna vaccines has also been tested in children between 5 and 11 years old, and the results are very good in terms of efficacy, safety and A decision has not yet been taken at the European Union level, whether or not to vaccinate these children, and we await, in addition to the indications that may come from regulatory agencies, also an analysis on the benefits that can be in vaccinating this population. .



If a vaccine is not dangerous it is good to use it, but you have to understand how necessary it is to do it.

The greatest advantage is to reach control of the epidemic first, but these are assessments that will have to be made in the coming weeks. "This is how Gianni Rezza expressed himself, responding to journalists during the press conference on the analysis of the data of the Covid Cabin Monitoring by Direction.

Keywords: vaccine, ema, pfizer-biontech, use, vaccines, vaccinations, age, children, light, comirnaty, covid, pfizer, authorization, production sites, yearsvaccini